Binding of a tritiated inverse agonist to cannabinoid CB1 receptors is increased in patients with schizophrenia

被引：37

作者：

Jenko, Kimberly J. ^{[1
]}

Hirvonen, Jussi ^{[1
]}

Henter, Ioline D. ^{[1
]}

Anderson, Kacey B. ^{[1
]}

Zoghbi, Sami S. ^{[1
]}

Hyde, Thomas M. ^{[2
,3
]}

Deep-Soboslay, Amy ^{[2
]}

Innis, Robert B. ^{[1
]}

Kleinman, Joel E. ^{[2
]}

机构：

[1] NIMH, Mol Imaging Branch, NIH, Bethesda, MD 20892 USA

[2] NIMH, Clin Brain Disorders Branch, NIH, Bethesda, MD 20892 USA

[3] Lieber Inst Brain Dev, Baltimore, MD 21205 USA

来源：

SCHIZOPHRENIA RESEARCH | 2012年 / 141卷 / 2-3期

基金：

美国国家卫生研究院;

关键词：

Cannabinoid; CB1; Schizophrenia; Dorsolateral prefrontal cortex; H-3]MePPEP; ANTERIOR CINGULATE CORTEX; PREFRONTAL CORTEX; EXPRESSION; DISORDER; DENSITY;

D O I：

10.1016/j.schres.2012.07.021

中图分类号：

R749 [精神病学];

学科分类号：

100205 ;

摘要：

This study sought to determine whether cannabinoid-1 (CB1) receptor binding was altered in the postmortem dorsolateral prefrontal cortex (DLPFC) of individuals with schizophrenia (schizophrenia; n = 47) compared to controls (n = 43). The CB1 receptor inverse agonist radioligand [H-3]MePPEP was used to measure specific binding to CB1 receptors. The specific binding of [H-3]MePPEP to CB1 receptors was 20% higher in patients with schizophrenia than in controls. Power analyses suggested that 53 subjects per group would be needed to detect a similar difference in vivo with positron emission tomography (PET) and the structurally related inverse agonist radioligand [F-18]FMPEP-d(2) (80% statistical power, p<0.05). Published by Elsevier B.V.

引用

页码：185 / 188

页数：4

共 50 条

[1] Hemopressin is an inverse agonist of CB1 cannabinoid receptors
Heimann, Andrea S.
Gomes, Lvone
Dale, Camila S.
Pagano, Rosana L.
Gupta, Achla
de Souza, Laura L.
Luchessi, Augusto D.
Castro, Leandro M.
Giorgi, Renata
Rioli, Vanessa
Ferro, Elmer S.
Devi, Lakshmi A.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (51) : 20588 - 20593
[2] An aromatic microdomain at the cannabinoid CB1 receptor constitutes an agonist/inverse agonist binding region
McAllister, SD
Rizvi, G
Anavi-Goffer, S
Hurst, DP
Barnett-Norris, J
Lynch, DL
Reggio, PH
Abood, ME
JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (24) : 5139 - 5152
[3] Taranabant.: Cannabinoid CB1 inverse agonist, Antiobesity drug
Cole, P.
Serradell, N.
Rosa, E.
Bolos, J.
DRUGS OF THE FUTURE, 2008, 33 (03) : 206 - 212
[4] Cannabinoid Discrimination and Antagonism by CB1 Neutral and Inverse Agonist Antagonists
Kangas, Brian D.
Delatte, Marcus S.
Vemuri, V. Kiran
Thakur, Ganesh A.
Nikas, Spyridon P.
Subramanian, Kumara V.
Shukla, Vidyanand G.
Makriyannis, Alexandros
Bergman, Jack
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2013, 344 (03): : 561 - 567
[5] Increased Expression of Cannabinoid CB1 Receptors in Achilles Tendinosis
Bjorklund, Emmelie
Forsgren, Sture
Alfredson, Hakan
Fowler, Christopher J.
PLOS ONE, 2011, 6 (09):
[6] The Cannabinoid CB1 Receptor in Schizophrenia
Borgan, Faith
Kokkinou, Michelle
Howes, Oliver
BIOLOGICAL PSYCHIATRY-COGNITIVE NEUROSCIENCE AND NEUROIMAGING, 2021, 6 (06) : 646 - 659
[7] PARANOID SCHIZOPHRENIA IS CHARACTERISED BY INCREASED CANNABINOID CB1 RECEPTOR BINDING IN THE DORSOLATERAL PREFRONTAL CORTEX
Zavitsanou, Katerina
Dalton, Victoria S.
SCHIZOPHRENIA RESEARCH, 2010, 117 (2-3) : 490 - 490
[8] Binding thermodynamics at the human cannabinoid CB1 and CB2 receptors
Merighi, Stefania
Simioni, Carolina
Gessi, Stefania
Varani, Katia
Borea, Pier Andrea
BIOCHEMICAL PHARMACOLOGY, 2010, 79 (03) : 471 - 477
[9] Cannabinoid CB1 receptors in epilepsy
Agar, E.
ACTA PHYSIOLOGICA, 2019, 227 : 27 - 27
[10] SR141716A is an inverse agonist at the human cannabinoid CB1 receptor
Landsman, RS
Burkey, TH
Consroe, P
Roeske, WR
Yamamura, HI
EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 334 (01) : R1 - R2

← 1 2 3 4 5 →